<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667507</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-CYTODEX</org_study_id>
    <nct_id>NCT04667507</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Aqueous Dexamethasone</brief_title>
  <official_title>The Pharmacokinetics of Aqueous Dexamethasone and the Inflammatory Cytokine Response After Treatment With a Dexamethasone Intracanalicular Insert - The CYTODEX Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frank A. Bucci, Jr., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bucci Laser Vision Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being done to measure the absorption of the DEXTENZA implant and inflammation&#xD;
      concentration levels in the eye.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics in Aqueous Humor Samples</measure>
    <time_frame>Measured 1-3 days, 6-8 days, 13-15 days, 19-23 days, and 26-31 days after Dextenza insertion</time_frame>
    <description>Concentration of dexamethasone in the aqueous humor will be determined by an independent laboratory using standardized high-pressure liquid chromatography and mass spectrometry assasys. Pharmacokinetic parameters determined from aqueous humor concentration will minimally include maximum concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics in Aqueous Humor Samples</measure>
    <time_frame>Measured 1-3 days, 6-8 days, 13-15 days, 19-23 days, and 26-31 days after Dextenza insertion</time_frame>
    <description>Concentration of inflammatory cytokines (IL-1 beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), IL-13, TNF alpha, and IFN gamma) in the aqueous humor will be determined by an independent laboratory using standardized high-pressure liquid chromatography and mass spectrometry assasys. Pharmacokinetic parameters determined from aqueous humor concentration will minimally include maximum concentration (Cmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between dexamethasone levels and inflammatory cytokines</measure>
    <time_frame>1-3 days, 6-8 days, 13-15 days, 19-23, or 26-31 days after Dextenza insertion</time_frame>
    <description>Test for statistically significant correlations between the aqueous concentrations of dexamethasone and inflammatory cytokines (IL-1 beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 (p70), IL-13, TNF alpha, and IFN gamma) over time</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Aqueous Dexamethasone</condition>
  <condition>Inflammatory Cytokine Response</condition>
  <arm_group>
    <arm_group_label>Dextenza (Group A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextenza (dexamethasone ophthalmic insert 0.4mg) 1-3 days prior to cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextenza (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextenza (dexamethasone ophthalmic insert 0.4mg) 6-8 days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextenza (Group C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextenza (dexamethasone ophthalmic insert 0.4mg) 13-15 days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextenza (Group D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextenza (dexamethasone ophthalmic insert 0.4mg) 19-23days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextenza (Group E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextenza (dexamethasone ophthalmic insert 0.4mg) 26-31 days prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will not receive Dextenza (dexamethasone ophthalmic insert 0.4mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Ophthalmic implant</intervention_name>
    <description>Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use</description>
    <arm_group_label>Dextenza (Group A)</arm_group_label>
    <arm_group_label>Dextenza (Group B)</arm_group_label>
    <arm_group_label>Dextenza (Group C)</arm_group_label>
    <arm_group_label>Dextenza (Group D)</arm_group_label>
    <arm_group_label>Dextenza (Group E)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male of female, aged 55 or older&#xD;
&#xD;
          -  Scheduled to undergo phacoemulsification with the intraocular lens (IOL) implantation&#xD;
             for the treatment of cataract&#xD;
&#xD;
          -  Willing to comply with study instructions, agree to make study appointments, and&#xD;
             complete the course of the study&#xD;
&#xD;
          -  Must sign an informed consent document indicating that they understand the purpose of&#xD;
             and procedures required for the study and are willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or contraindication to the test article or its components&#xD;
&#xD;
          -  Presence of any ocular abnormality or significant illness that, in the investigator's&#xD;
             opinion, could affect the subject's health&#xD;
&#xD;
          -  History of any illness that could be expected to interfere with the study&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, would compromise the&#xD;
             well-being of the subject or study&#xD;
&#xD;
          -  May not be currently using topical or systemic steroids or NSAIDs during the course of&#xD;
             the study or within 4 weeks prior to enrolling in the study other than Dextenza and&#xD;
             Omidria&#xD;
&#xD;
          -  Subject has active corneal, conjunctival, or canalicular infections, including:&#xD;
&#xD;
          -  Epithelial herpes simplex keratitis (dendritic keratitis)&#xD;
&#xD;
          -  Vaccini&#xD;
&#xD;
          -  Varicella&#xD;
&#xD;
          -  Mycobacterial infections&#xD;
&#xD;
          -  Fungal diseases of the eye&#xD;
&#xD;
          -  Dacryocystitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A Bucci, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Laser Vision Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucci Laser Vision</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bucci Laser Vision Institute</investigator_affiliation>
    <investigator_full_name>Frank A. Bucci, Jr., M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

